Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.

Published in: Expert review of anticancer therapy (2023)

1-year adjuvant pembrolizumab treatment of stage IIB/C melanoma patients significantly reduces recurrence or death risk. The safety profile of adjuvant treatment is not different from previously reported and is manageable. Longer follow-up is required to fully understand the efficacy and safety of adjuvant therapy for stage II melanoma, as the number of patients needed to treat is twice as high as for stage III patients.

Keyphrases

end stage renal disease
ejection fraction
early stage
newly diagnosed
peritoneal dialysis
patient reported outcomes